Visualisation of BLI data of OF-1 mice infected with <i>T.b. brucei</i>, <i>T.b. rhodesiense</i> and <i>T.b. gambiense</i>.

<p>OF-1 mice (n = 3) were infected with <i>T.b. brucei</i> AnTaR 1 RLuc (A–D), <i>T.b. brucei</i> AnTaR 1 CBR (E–H), <i>T.b. brucei</i> AnTaR 1 P9 (I–L), <i>T.b. rhodesiense</i> RUMPHI CBR (M–P), <i>T.b. gambiense</i> LiTaR 1 CBR (Q–R) and their luminescence was measured in BLI using their respective substrates. Rows represent measurements at 1, 4, 18 and 26 days post-infection.</p

Characteristics of wild-type and luminescent strains.

<p>Comparison of (A) relative luciferase activity (values are the mean ± SD from 6 to 11 cultures) (B) doubling time (values are the mean ± SD from 3 cultures) and (C) hygromycin resistance IC₅₀ (values are the mean ± SD from 2 to 7 cultures).</p

Definition of ROI.

<p>BLI data were analysed in function of 3 ROIs; (A) abdomen, (B) thorax and (C) head.</p

Visualisation of BLI data in untreated and CPA-treated OF-1 mice infected with <i>T.b. gambiense</i>.

<p>OF-1 mice (n = 3) were infected with <i>T.b. gambiense</i> 348 BT RLuc without (A–E) or with CPA treatment (F–J) and their luminescence was measured with ViviRen or were infected with <i>T.b. gambiense</i> 348 BT CBR without (K–P) or with (Q–V) CPA treatment and their luminescence was measured with D-luciferin. Rows represent measurements at 1, 3, 7, 11, 43 (for RLuc) and 60 days post-infection (only CBR). In square P one mouse woke up from anesthesia just before the end of acquisition.</p

Drug sensitivity profiles of wild-type and luminescent strains.

<p>IC₅₀ (mean ± SD) of wild-type and luminescent strains against (A) eflornithine (values are the mean ± SD from 4 to 9 cultures), (B) nifurtimox (values are the mean ± SD from 4 to 9 cultures), (C) diminazene diaceturate (values are the mean ± SD from 2 cultures), (D) melarsoprol (values are the mean ± SD from 4 to 9 cultures), (E) suramin (values are the mean ± SD from 4 to 9 cultures) and (F) pentamidine isethionate (values are the mean ± SD from 2 cultures).</p

Quantification of BLI data of OF-1 mice infected with luminescent <i>T.b. brucei</i>, <i>T.b. rhodesiense</i> and <i>T.b. gambiense</i>.

<p>OF-1 mice (n = 3) were infected with <i>T.b. brucei</i> AnTaR 1 wild-type, <i>T.b. brucei</i> AnTaR 1 RLuc, <i>T.b. brucei</i> AnTaR 1 CBR, <i>T.b. brucei</i> AnTaR 1 P9, <i>T.b. rhodesiense</i> RUMPHI CBR, <i>T.b. gambiense</i> LiTaR 1 CBR and their luminescence was measured at 1, 4, 7, 18 and 26 post-infection in BLI using their respective substrates. The BLI data were divided in 3 ROIs; (A) abdomen, (B) thorax and (C) head and expressed as ph s⁻¹ cm⁻² sr⁻¹.</p

List of <i>T.b.</i> strains and their history.

<p>List of <i>T.b.</i> strains and their history.</p

Visualisation of <i>ex vivo</i> brain BLI data obtained from mice infected with different luminescent strains.

<p>At 26 days post-infection for <i>T.b. brucei</i> AnTaR 1 and <i>T.b. rhodesiense</i> RUMPHI and at 43 and 60 days post-infection for <i>T.b. gambiense</i> 348 BT brains were extracted and immersed in PBSG and substrate. (A–B) <i>T.b. gambiense</i> 348 BT CBR, CPA-treated, with D-luciferin; (C) <i>T.b. gambiense</i> 348 BT CBR, untreated, with D-luciferin ;(D) uninfected with D-luciferin; (E) <i>T.b. gambiense</i> 348 BT RLuc, CPA-treated with ViviRen; (F–H) <i>T.b. rhodesiense</i> RUMPHI CBR with D-luciferin; (I) <i>T.b. brucei</i> AnTaR 1 CBR with D-luciferin; (J) <i>T.b. brucei</i> AnTaR 1 P9 with D-luciferin.</p

Sensitivity and specificity of PCR on blood for diagnosis of HAT.

<p>Note. CI = confidence interval.</p

Classification of study participants according to reference standards for diagnosis, staging and follow-up (FU).

<p>At each follow-up time point, the number of patients attending is given. Patient groups reaching a final outcome of treatment failure during follow-up and excluded from analysis at subsequent time points, are indicated with an arrow.</p